Serum Institute of India (SII), the world’s largest maker of vaccines by volume, is mass-producing the vaccine candidate developed by the University of Oxford, which started testing it on humans last week, and is a leader in the global race to develop an antidote to the novel coronavirus.
Race for vaccine
In an interview to a various news organizations, Adar Poonawala, the Chief Executive Officer (CEO) of SII, based in the western Indian city of Pune, says he is taking the risk of initiating production even before the vaccine has reached advanced clinical trials and will sell the vaccine, if developed, for just 1,000 Indian Rupees or 12 Euros per dose.
